Resources
For the latest in precision medicine, sign up for our monthly newsletter to be among the first to receive
exclusive insights, in-depth market analyses, and expert articles directly to your inbox
On-demand webinar presented by Joel McDade, PhD, Sr. Commercial Business Development Manager, Quantum-Si and Bonnie Lun, PhD, Field Application Scientist
Challenges and Strategies for the Application of Omics and Spatial Technologies
A concise report featuring insights from the prominent thought leaders of Omics 2023 and Spatial 2024
A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics
On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient
Top R&D Stories of 2023
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Diagnostic Development
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Biomarker Analysis
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Personalised Medicine
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Biomarker Discovery & Development
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Liquid Biopsies
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Personalised Medicine
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Biomarker Discovery & Development
A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics
On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient
Clinical Diagnostics
Accelerate Protein Screening by Sequencing Protein Barcodes on Platinum®
On-demand webinar presented by Joel McDade, PhD, Sr. Commercial Business Development Manager, Quantum-Si and Bonnie Lun, PhD, Field Application Scientist
Liquid Biopsies
Feinstein Institutes Links Blood Biomarkers to Psychosis in Alzheimer's Patients
The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis.
Spatial Analysis
Challenges and Strategies for the Application of Omics and Spatial Technologies
A concise report featuring insights from the prominent thought leaders of Omics 2023 and Spatial 2024
Genomic Biomarkers
ZERO Precision Medicine Programme Reports Outstanding Efficacy in High-Risk Paediatric Cancers
The first-of-its-kind trial presents a positive outlook for cancer types with historically poor survival rates.
Genomic Biomarkers
Hope for New Prognostic Biomarkers & Therapeutic Options From Tumour Metabolism-Targeting Breast Cancer Study
Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers.
Subscribe to Our Newsletter
Sign up for our monthly newsletter to
keep up with all things discovery